Polyrizon's NASARIX™ Allergy Blocker Clears Biocompatibility Testing, Paving Way for Human Trials
PLRZ has more than doubled off its 52-week low of $2.88 on light trading volume (0.4× avg).
Summary
Polyrizon announced successful results from its NASARIX™ Allergy Blocker biocompatibility program, with all biological safety tests meeting acceptance criteria. This critical pre-clinical milestone de-risks the product and directly supports its advancement towards first-in-human clinical trials. The news follows recent announcements of securing clinical sites and receiving IRB approval for the NASARIX™ trial, indicating a clear progression for the company's lead product.
At the time of this announcement, PLRZ was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $2.88 to $18.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.